Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
28.28 USD
-1.67%
Market Closed
Updated:
May 4, 2024
Royalty Pharma PLC
Cash from Operating Activities
|
Royalty Pharma PLC
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Royalty Pharma PLC
NASDAQ:RPRX
|
Cash from Operating Activities
$3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Royalty Pharma PLC's Cash from Operating Activities?
Cash from Operating Activities
3B
USD
3B
USD
Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's Cash from Operating Activities amounts to 3B USD.
What is Royalty Pharma PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
13%
13%
Over the last year, the Cash from Operating Activities growth was 39%. The average annual Cash from Operating Activities growth rates for Royalty Pharma PLC have been 14% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
